Showing results (221-230 of 261) with videos related to

Sort By:
Pageof 27
The Journal of Clinical Investigation|September 9, 2025
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIVMárton Kolossváry, Irini Sereti, Markella V Zanni, et al.
JACC. Advances|September 10, 2024
Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIVChristopher deFilippi, Sara McCallum, Markella V Zanni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances|January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trialRomit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Open Forum Infectious Diseases|April 10, 2025
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial CohortEmma Davies Smith, Carlos Malvestutto, Heather J Ribaudo, et al.
AIDS (London, England)|December 16, 2022
Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIVPamela S Douglas, Sara McCallum, Michael T Lu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2023
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE CohortBorek Foldyna, Thomas Mayrhofer, Markella V Zanni, et al.
AIDS (London, England)|July 25, 2022
Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease riskKathleen V Fitch, Sara A McCallum, Kristine M Erlandson, et al.
The Lancet. HIV|June 7, 2025
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysisCarl J Fichtenbaum, Carlos D Malvestutto, Maya G Watanabe, et al.
Pageof 27